Hypertrophic cranial pachymeningitis: Two cases report and literature review

doi:10.3969/j.issn.1004-583X.2021.07.013

Abstract

Abstract:

Hypertrophic cranial pachymeningitis(HCP) is a clinical disease involving local or diffuse thickening of the dura mater, with or without related inflammation. Due to lower incidence for HCP and diversified clinical manifestations, the difficulty of clinical diagnosis significantly increased. In this article, recurrent headache in two HCP cases were regarded as clinical feature, one of them showed optic nerve damage, the headache improved significantly after hormone treatment. The disease was discussed in conjunction with literature review.

Key words: hypertrophic cranial pachymeningitis, headache, cranial neuropathy, diagnosis

CLC Number:

R515.2

Wang Lu, Zeng Zhaohao, Luo Hong, Cen Haimei, Zhang Yu. Hypertrophic cranial pachymeningitis: Two cases report and literature review[J]. Clinical Focus, 2021, 36(7): 637-640.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.07.013

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I7/637

Figures/Tables 2

References 23

[1]	Choi HA, Lee MJ, Chung CS. Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis[J]. J Neurol, 2017,264(4):724-732. doi: 10.1007/s00415-017-8416-0 URL
[2]	Yao Y, Wang Z, Yang W, et al. Hypertrophic cranial pachymeningitis caused by pseudomonas stutzeri associated with connective tissue disease[J]. Ann Pharmacother, 2015,49(6):745-746. doi: 10.1177/1060028015569271 pmid: 25975997
[3]	Kim EH, Kim SH, Jin MC, et al. Immunoglobulin G4-related hypertrophic pachymeningitis involving cerebral parenchyma[J]. J Neurosurg, 2011,115(6):1242-1247. doi: 10.3171/2011.7.JNS1166 URL
[4]	Wallace ZS, Carruthers MN, Khosroshahi A, et al. IgG4-related disease and hypertrophic pachymeningitis[J]. Medicine (Baltimore), 2013,92(4):206-216. doi: 10.1097/MD.0b013e31829cce35 URL
[5]	Yonekawa T, Murai H, Utsuki S, et al. A nationwide survey of hypertrophic pachymeningitis in Japan[J]. J Neurol Neurosurg Psychiatry, 2014,85(7):732-739. doi: 10.1136/jnnp-2013-306410 pmid: 24273222
[6]	Han F, Zhong DR, Hao HL, et al. Cranial and lumbosacral hypertrophic pachymeningitis associated with systemic lupus erythematosus: A case report[J]. Medicine (Baltimore), 2016,95(39):e4737. doi: 10.1097/MD.0000000000004737 URL
[7]	Thurtell MJ, Keed AB, Yan M, et al. Tuberculous cranial pachymeningitis[J]. Neurology, 2007,68(4):298-300. pmid: 17242338
[8]	Iwasaki S, Ito K, Sugasawa M. Hypertrophic cranial pachymeningitis associated with middle ear inflammation[J]. Otol Neurotol, 2006,27(7):928-933. doi: 10.1097/01.mao.0000231498.61781.ec URL
[9]	Charleston L 4th, Cooper W. An Update on idiopathic hypertrophic cranial pachymeningitis for the headache practitioner[J]. Curr Pain Headache Rep, 2020,24(10):57. doi: 10.1007/s11916-020-00893-5 URL
[10]	Kupersmith MJ, Martin V, Heller G, et al. Idiopathic hypertrophic pachymeningitis[J]. Neurology, 2004,62(5):686-694. pmid: 15007115
[11]	Okuma H, Kobori S, Shinohara Y, et al. A case of hypertrophic pachymeningitis with prolonged headache, attributable to Epstein-Barr virus[J]. Headache, 2007,47(4):620-622. doi: 10.1111/j.1526-4610.2007.00763_4.x URL
[12]	Dash GK, Thomas B, Nair M, et al. Clinico-radiological spectrum and outcome in idiopathic hypertrophic pachymeningitis[J]. J Neurol Sci, 2015,350(1-2):51-60. doi: 10.1016/j.jns.2015.02.013 URL
[13]	Huang K, Xu Q, Ma Y, et al. Cerebral venous sinus thrombosis secondary to idiopathic hypertrophic cranial pachymeningitis: Case report and review of literature[J]. World Neurosurg, 2017, 106:1052.e13-1052.e21. doi: 10.1016/j.wneu.2017.07.002 URL
[14]	Park IS, Kim H, Chung EY, et al. Idiopathic hypertrophic cranial pachymeningitis misdiagnosed as acute subtentorial hematoma[J]. J Korean Neurosurg Soc, 2010,48(2):181-184. doi: 10.3340/jkns.2010.48.2.181 URL
[15]	Yao A, Jia L, Wang B, et al. Idiopathic hypertrophic pachymeningitis mimicking meningioma with occlusion of superior sagittal sinus: Case report and review of literature[J]. World Neurosurg, 2019,127:534-537. doi: S1878-8750(19)30874-5 pmid: 30928581
[16]	Chen H, Zhang W, Jing J, et al. The clinical and imaging features of hypertrophic pachymeningitis: a clinical analysis on 22 patients[J]. Neurol Sci, 2019,40(2):269-274. doi: 10.1007/s10072-018-3619-4 pmid: 30377845
[17]	Williams T, Marta M, Giovannoni G. IgG4-related disease: A rare but treatable cause of refractory intracranial hypertension[J]. Pract Neurol, 2016,16(3):235-239. doi: 10.1136/practneurol-2015-001275 pmid: 26657781
[18]	Utsuki S, Kijima C, Fujii K, et al. Investigation of IgG4-positive cell infiltration in biopsy specimens from cases of hypertrophic pachymeningitis[J]. Clin Neuropathol, 2013,32(2):84-90. doi: 10.5414/NP300496 URL
[19]	Jang Y, Lee ST, Jung KH, et al. Rituximab treatment for idiopathic hypertrophic pachymeningitis[J]. J Clin Neurol, 2017,13(2):155-161. doi: 10.3988/jcn.2017.13.2.155 URL
[20]	Tariq R, Ahmed R. Tuberculous hypertrophic pachymeningitis presenting as visual blurring and headaches[J]. J Pak Med Assoc, 2012,62(9):966-968.
[21]	Uchida H, Ogawa Y, Tominaga T. Marked effectiveness of low-dose oral methotrexate for steroid-resistant idiopathic hypertrophic pachymeningitis: Case report[J]. Clin Neurol Neurosurg, 2018,168:30-33. doi: 10.1016/j.clineuro.2018.02.035 URL
[22]	Bi Z, Shang K, Cao J, et al. Hypertrophic pachymeningitis in chinese patients: Presentation, radiological findings, and clinical course[J]. Biomed Res Int, 2020,2020:2926419.
[23]	Yokoseki A, Saji E, Arakawa M, et al. Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody[J]. Brain, 2014,137(Pt 2):520-536. doi: 10.1093/brain/awt314 pmid: 24271323